The Odds Of A Fed Rate Hike In June Just Got Smaller

George Yacik - INO.com Contributor - Fed & Interest Rates


Still think the Federal Reserve will raise interest rates at its monetary policy meeting next week? Last Friday’s jobs report for May should make you rethink that notion. But it’s not the only reason.

Prior to the release of the report – which showed that the economy added just 138,000 jobs last month, nearly 50,000 below expectations, while the previous two months were revised downward by 66,000– the market consensus called for the Fed to raise rates by 25 basis points at its June 13-14 meeting. That doesn’t seem like such a sure thing anymore.

After its last meeting on May 2-3, when it took no action on rates largely because of a weaker-than-expected economy in the first quarter, the Fed said it expected the slowdown was “likely to be transitory.” Now, however, we have a pretty substantial body of evidence that indicate fairly strongly, if not consistently, that the slowdown has continued well into the second quarter. Continue reading "The Odds Of A Fed Rate Hike In June Just Got Smaller"

We Need To Keep The CFPB

George Yacik - INO.com Contributor - Fed & Interest Rates


President Trump’s first federal budget proposal got a lot of grief over the past week from both Republicans – some of whom say it’s “dead on arrival” – and Democrats – some of whom claim it’s actually going to kill people. But one small part of the plan got relatively little notice, maybe because it was on the next-to-last page of the document. That was the huge cuts proposed for the Consumer Financial Protection Bureau (CFPB), essentially abolishing it in a few years.

The Trump proposal would cut the agency’s budget by $145 million in 2018, a one-year reduction of more than 20%, with the cuts increasing to more than $700 million by 2021, when it would essentially be defunded.

I think that would be a terrible mistake. For those of you who disagree, I have two words for you: Wells Fargo (WFC). Continue reading "We Need To Keep The CFPB"

Did The Fed Jump The Gun? Now What?

George Yacik - INO.com Contributor - Fed & Interest Rates


Based on the recent direction of the U.S. economy and the drop in Treasury bond yields to six-month lows, it would appear that the Federal Reserve may have been a little too hasty in raising interest rates and ending monetary accommodation. So how will the markets – both stocks and bonds – react if the Fed has to swallow its pride and need to stuff the genie back in the bottle?

As we know, since Donald Trump was elected last November, the Fed has raised the federal funds rate twice, plus promised at least two more increases by the end of this year. At the same time, it’s also said that it plans to start trimming its massive $4.5 trillion securities portfolio before year-end. All of that action has been predicated on the economy growing and potentially over-heating – i.e., causing too much inflation – under President Trump’s stimulative policies, including tax cuts, deregulation and repealing and replacing Obamacare.

But what happens if those assumptions don’t actually become a reality, which is what seems to be happening right now? Will the Fed suddenly start lowering interest rates again, or at least put off its plans for future rate increases? And will it also put on hold its balance sheet reduction plan? Continue reading "Did The Fed Jump The Gun? Now What?"

Issue #12: Trump’s Love-Hate Relationship With Pharma, Amgen Promises Jobs and Sector Earnings Underway

INO Health & Biotech Stock Guide

Preview Issue #12 - March 20, 2017

BIOTECH, HEALTH & PHARMA NEWS

President Trump met with a group of pharmaceutical executives at the White House where he voiced his concerns over their pricing, stating that pricing “has been astronomical.” In the same meeting, President Trump said “You folks have done a very great job over the years,” and “but we have to get the prices down.” In a separate press conference, Trump said that big pharma was “getting away with murder”. Big pharma companies are joining forces as of late to address the price increases that the public and governmental officials have been demanding. Allergan (AGN), J&J (JNJ), Novo Nordisk (NVO) and AbbVie (ABBV) have committed to limiting any annual drug pricing increases to less than 10%. J&J went further stating that they will be publishing an annual report regarding its portfolio and the price increases they’ve implemented. AbbVie released data on its increases as well stating that Humira was increased by 8.4% with an only once annual increase moving forward. Merck (MRK) becomes the latest pharma to join this drug pricing transparency coalition. Merck raised list prices by an average of 9.6% with an average net price increase of 5.5%. This transparency is a step in the right direction to appease the general public and governmental officials.

President Donald Trump

Figure 1 - President Trump met with pharmaceutical industry leaders at the White House on Tuesday. From left are PhRMA President Stephen Ubl, Merck CEO Kenneth Frazier, Trump, Celgene CEO Robert Hugin and Amgen CEO Robert Bradway. (Evan Vucci / Associated Press)

WHAT'S NEXT

Continue reading "Issue #12: Trump’s Love-Hate Relationship With Pharma, Amgen Promises Jobs and Sector Earnings Underway"

IBB - The Political Tug-Of-War Rages On

Noah Kiedrowski - INO.com Contributor - Biotech


Donald Trump is back at it again via Twitter and once again he has ignited the political tug-of-war between potential policy changes and Wall Street. The overall healthcare sector has become volatile on the heels of any statement or tweet from Donald Trump. Shortly after the inauguration, Trump held a press conference and stated that drug companies are “getting away with murder” when speaking to the drug pricing debate. Now he’s come out and stated that he’s working on a “new system where there will be competition in the drug industry.” Every time any of these remarks are tweeted, they immediately result in a downtrend across the entire biotech cohort, this time was no exception. The iShares Biotechnology Index ETF (NASDAQ:IBB) traded down 1.7% or $5 per share once tweeted. The healthcare sector has been faced with an uncertain and volatile political backdrop. The overall healthcare umbrella has become sensitive to any tweet from President Trump as he vows to bring down drug prices. Although he’s pursuing his agenda against drug pricing, IBB has become resilient as many of these threats may have already been priced-in as seen in many healthcare-related stocks that have seen sharp and sustained sell-offs. Ostensibly, many of these stocks are trading at multiyear low P/E ratios and as a cohort (gauged via the IBB proxy) looks to be less sensitive to tweets/threats and continues to test the $300 barrier.

IBB Chart
Figure 1 – IBB price activity and resilience over the previous 6 months with pronounced volatility that coincides with political rhetoric against drug pricing

The Drug Pricing Transparency Coalition

Many large-cap pharma companies have created an unofficial drug pricing coalition to provide transparency in an effort to separate themselves from a handful of egregious price increases to contend with Trump’s aim at the drug companies. Continue reading "IBB - The Political Tug-Of-War Rages On"